Positions

Overview

  • Vice President, Drug Discovery, Southern Research Institute
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Retraction notice to "SRI36160 is a specific inhibitor of Wnt/-catenin signaling in human pancreatic and colorectal cancer cells" [Canc. Lett. 389C (2017) 41-48].Cancer Letters.  422:131. 2018
    2018 Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.International Journal of Molecular Sciences.  19. 2018
    2018 Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotidesNucleic Acids Research.  46:1601-1613. 2018
    2017 Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease.Collagen and related research.  68-69:28-43. 2017
    2017 Predicting radiotherapy response for patients with soft tissue sarcoma by developing a molecular signature.Oncology Reports.  38:2814-2824. 2017
    2017 Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain.Oncotarget.  8:91459-91470. 2017
    2017 Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.Oncotarget.  8:37568-37583. 2017
    2017 Development of a radiosensitivity gene signature for patients with soft tissue sarcoma.Oncotarget.  8:27428-27439. 2017
    2017 Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer".Journal of Medicinal Chemistry.  60:7615. 2017
    2016 SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.Cancer Letters.  389:41-48. 2016
    2016 Identification of Small Molecule Inhibitors of Human Cytochrome c Oxidase That Target Chemoresistant Glioma Cells.Journal of Biological Chemistry.  291:24188-24199. 2016
    2016 Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.American Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2016 Discovery of a novel inhibitor of kinesin-like protein KIFC1.Biochemical Journal.  473:1027-1035. 2016
    2016 Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.Future Virology.  11:187-195. 2016
    2016 Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.American Journal of Pathology.  186:678-690. 2016
    2015 High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.Nucleic Acids Research.  43:1987-1996. 2015
    2014 AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.Journal of Biomolecular Screening.  19:1338-1349. 2014
    2014 Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.Journal of Biological Chemistry.  289:32937-32951. 2014
    2013 Role of adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy.Current Pharmaceutical Design.  19:5755-5763. 2013
    2012 3D Cell Cultures. Mimicking In Vivo Tissues for Improved Predictability in Drug DiscoveryAnnual Reports in Medicinal Chemistry.  47:367-378. 2012
    2012 Process development and optimization for production of a potassium ion channel blocker, ICA-17043Organic Process Research and Development.  16:1385-1392. 2012
    2012 Frizzled7 as an emerging target for cancer therapy.Cellular Signalling.  24:846-851. 2012
    2012 The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.Journal of Cellular Biochemistry.  113:13-18. 2012
    2011 N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.ACS Medicinal Chemistry Letters.  2:481-484. 2011
    2004 Design of a gene family screening library targeting G-protein coupled receptors.Journal of molecular graphics.  23:15-21. 2004
    2004 Neuronal nicotinic acetylcholine receptors as drug targets.Expert Opinion on Therapeutic Targets.  8:61-64. 2004
    2003 The design and synthesis of novel orally active inhibitors of AP-1 and NF-kappaB mediated transcriptional activation. SAR of in vitro and in vivo studies.Bioorganic and Medicinal Chemistry Letters.  13:4077-4080. 2003
    2000 Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide].Journal of Medicinal Chemistry.  43:3995-4004. 2000
    2000 Novel inhibitors of AP-1 and NF-kappaB mediated gene expression: structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)++ +pyrimidi ne-5-carboxylate.Bioorganic and Medicinal Chemistry Letters.  10:1645-1648. 2000
    2000 Designing chiral libraries for drug discovery.Drug Discovery Today.  5:364-372. 2000
    2000 Synthesis and structure-activity relationship studies of conformationally restricted, analogs of 2-chloro-4-trifluoromethylpyrimidine- 5-[N-(3',5'-bis(trifluoromethyl)phenyl)]carboxamideMedicinal Chemistry Research.  10:19-29. 2000
    1999 Developments in solution-phase combinatorial chemistry.Current Opinion in Drug Discovery and Development.  2:377-384. 1999
    1998 A novel and T cell specific dual inhibitor of NF-κB and AP-1 suppresses alloreactivity in mice through its antiproliferative effect mediated by inhibition of IL-2 productionFederation proceedings.  12. 1998
    1998 2-Chloro-4-(trifluoromethyl)pyrimidine-5-N-(3',5'- bis(trifluoromethyl)phenyl)-carboxamide: a potent inhibitor of NF-kappa B- and AP-1-mediated gene expression identified using solution-phase combinatorial chemistry.Journal of Medicinal Chemistry.  41:413-419. 1998
    1998 A general and regiospecific synthesis of 5,8-disubstituted α- tetralonesSynthetic Communications.  28:3491-3502. 1998
    1997 Novel approaches for the treatment of inflammatory diseases: Inhibitors of NF-κB and AP-1Current Pharmaceutical Design.  3:515-528. 1997
    1997 A novel inhibitor of nuclear factor-kappa B and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo.Transplantation Proceedings.  29:1269-1270. 1997
    1997 Ion-exchange resins for solution phase parallel synthesis of chemical librariesTetrahedron Letters.  38:513-516. 1997
    1997 Traceless linker: Oxidative activation and displacement of a sulfur-based linkerTetrahedron Letters.  38:211-214. 1997
    1996 Peptide inhibitors of IκB protease: Modification of the C-termini of Z-LLF-CHOBioorganic and Medicinal Chemistry Letters.  6:2925-2930. 1996
    1996 SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo.Transplantation Proceedings.  28:3106-3109. 1996
    1996 Use of pentafluorophenyl esters for one-pot protection/activation of amino and thiol carboxylic acidsTetrahedron Letters.  37:4915-4918. 1996
    1995 Synthesis of Boxazomycin B and related analogsTetrahedron Letters.  36:7213-7216. 1995
    1994 Synthesis and antibacterial activity of new quinolones containing a 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl] moiety. Gram-positive agents with excellent oral activity and low side-effect potential.Journal of Medicinal Chemistry.  37:733-738. 1994
    1994 An efficient method for the synthesis of (R)-3-(1-amino-1-methylethyl)pyrrolidines for the antiinfective agent, PD 138312Tetrahedron: Asymmetry.  5:1131-1134. 1994
    1993 Stereoselective Michael additions of nitromethane yielding 3R(1S N-substituted aminoethyl)pyrrolidinesTetrahedron Letters.  34:7529-7532. 1993
    1993 Quinolone antibacterials containing the new 7-[3-(1-aminoethyl)-1- pyrrolidinyl] side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in vivo efficacy.Journal of Medicinal Chemistry.  36:871-882. 1993
    1993 High capacity in vitro micronucleus assay for assessment of chromosome damage: results with quinolone/naphthyridone antibacterials.Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis.  298:227-236. 1993
    1993 3-Ethenyl, 3-ethynyl, 3-aryl, and 3-cyclopropyl-2,4,6-trifluorobenzoic acids: Useful intermediate in the synthesis of quinolone antibacterialsTetrahedron Letters.  34:281-284. 1993
    1992 Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.Journal of Medicinal Chemistry.  35:4745-4750. 1992
    1992 Development of radioimmunoassays for measurement of the specific bronchodilator procaterol in human urine and plasmaJournal of Clinical Immunoassay.  15:258-264. 1992
    1992 Synthesis of chiral 3-substituted-3-aminomethyl-pyrrolidines and related compoundsMathematical Problems in Engineering.  29:1441-1448. 1992
    1992 Antibacterial Agents, Targets and ApproachesAnnual Reports in Medicinal Chemistry.  27:119-128. 1992
    1992 Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.International Journal of Radiation Oncology - Biology - Physics.  22:545-548. 1992
    1992 Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.International Journal of Radiation Oncology - Biology - Physics.  22:549-551. 1992
    1992 Synthesis of chiral 3‐substituted‐3‐aminomethyl‐pyrrolidines and related compoundsJournal of Heterocyclic Chemistry.  29:1441-1448. 1992
    1992 The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).Journal of Pharmacology and Experimental Therapeutics.  260:319-326. 1992
    1991 Synthesis and evaluation of a series of 3,5-disubstituted benzisoxazole-4,7-diones. Potent radiosensitizers in vitro.Journal of Medicinal Chemistry.  34:3290-3294. 1991
    1991 A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.Journal of Medicinal Chemistry.  34:2484-2488. 1991
    1991 Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells.Radiation Research.  126:367-371. 1991
    1991 Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase.Anticancer Drug Design.  6:107-117. 1991
    1991 Dual-function radiosensitizers. Alpha-[[(2-bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol and related compounds: preparation via an aziridine equivalent.Journal of Medicinal Chemistry.  34:1207-1209. 1991
    1991 Chapter 16. RadiosensitizersAnnual Reports in Medicinal Chemistry.  26:151-160. 1991
    1991 Inhibitors of poly(ADP-ribose) polymerase (ADPRP): Potential chemotherapeutic agentsDrugs of the future.  16:723-739. 1991
    1990 Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.Journal of Medicinal Chemistry.  33:2603-2610. 1990
    1988 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach.Journal of Medicinal Chemistry.  31:2103-2107. 1988
    1987 8-Amino-9-substituted guanines: potent purine nucleoside phosphorylase (PNP) inhibitors.Agents and actions.  21:253-256. 1987
    1987 Approaches to the Synthesis of Ring C Transposed Progesterone Analogues. rac -7β,15α-Ethano-11,12-seco-11,19-bisnor-17α-pregn-4-ene-3,20-dione and rac-4,4-Dimethyl-7,7-(ethylenedioxy)-(4aα,4bβ,8aα, 10aβ)-perhydro-3-phenanthrenoneJournal of Organic Chemistry.  52:2263-2273. 1987
    1986 Inhibitors of human purine nucleoside phosphorylase. Synthesis, purine nucleoside phosphorylase inhibition, and T-cell cytotoxicity of 2,5-diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two thio isosteres of 8-aminoguanine.Journal of Medicinal Chemistry.  29:1804-1806. 1986
    1982 Relative affinity of 17 alpha- and/or 21-esters and 17 alpha, 21-diesters of cortisol for a glucocorticoid receptor from rat thymocytes.Journal of Medicinal Chemistry.  25:747-749. 1982
    1980 Effect Of C-21 Substituents on the Elimination of a 17α-Acyloxy Group from 17α-(Acyloxy)-20-Oxo SteroidsJournal of Organic Chemistry.  45:2012-2013. 1980

    Book

    Year Title Altmetric
    2006 Antiarrhythmic Agents.  Ed. 41.  2006

    Research Overview

  • Keywords - New Therapies for Cancer, Infectious Diseases, and Neurological Diseases and Disorders
  • Education And Training

  • Doctor of Philosophy in Medicinal/Pharmaceutical Chemistry, State University of New York System : Buffalo
  • Full Name

  • Mark Suto
  • Blazerid

  • sutomjs